People · Operator

Ron Tilles

Named in public records as an officer, director or promoter · active 2010–2022 · Pharmaceuticals, Other Technology, Biotech / Pharma

3
Companies
5
Filings
$157.0M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Turing Pharmaceuticals AGPharmaceuticalsSeries C$153.0M$3.2B2015
Quantumid Technologies IncOther TechnologySeed$3.2M$85.2M2010
Pyros Pharmaceuticals, Inc.Biotech / PharmaPre-Seed$880K$8.1M2022
Operator network

Ron Tilles at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Michael Harrison · 8 companies · 1 sharedMichael HarrisonMartin Shkreli · 3 companies · 1 sharedMartin ShkreliAlan Geller · 1 companies · 1 sharedAlan GellerHoward Dorfman · 1 companies · 1 sharedHoward DorfmanWalter Blum · 1 companies · 1 sharedWalter BlumChristopher Cheever · 1 companies · 1 sharedChristopher Cheev…Milind Tavshikar · 1 companies · 1 sharedMilind TavshikarPrasanna Gogwekar · 1 companies · 1 sharedPrasanna GogwekarMichael Smith · 20 companies · 1 sharedMichael SmithEdwin Urrutia · 1 companies · 1 sharedEdwin UrrutiaTuring Pharmaceuticals AG · $153.0M raisedTuring Pharmaceutical…Quantumid Technologies Inc · $3.2M raisedQuantumid Technologie…Pyros Pharmaceuticals, Inc. · $0.9M raisedPyros Pharmaceuticals…Ron TillesRT
Ron Tilles Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ron Tilles on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael Smith120
Michael Harrison18
Martin Shkreli13
Edwin Urrutia11
Christopher Cheever11
Alan Geller11
Walter Blum11
Howard Dorfman11
Milind Tavshikar11
Prasanna Gogwekar11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.